Suchergebnisse
Suchergebnisse:
Matthew Meyerson is a cancer genomics researcher and director of the Center for Cancer Genome Discovery at DFCI. He leads the lung cancer disease working group of TCGA and has discovered many cancer genes and pathogens.
Matthew Langer Meyerson (born June 4, 1963) is an American pathologist and the Charles A. Dana Chair in Human Cancer Genetics at the Dana-Farber Cancer Institute. He is also director of the Center for Cancer Genomics at the Dana-Farber Cancer Institute, and the Director of Cancer Genomics at the Broad Institute of MIT and Harvard.
Matthew Meyerson is a professor and director at Dana-Farber Cancer Institute and Harvard Medical School. He studies the causes and mechanisms of lung and colon cancers using genomic approaches and genome-inspired discovery.
11963. 2004. Signatures of mutational processes in human cancer. LB Alexandrov, S Nik-Zainal, DC Wedge, SAJR Aparicio, S Behjati, ... Nature 500 (7463), 415-421. , 2013. 9794. 2013. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Matthew Langer Meyerson. Professor of Genetics and Medicine. We strive to discover genomic and infectious causes for human cancers. We then seek to apply these discoveries to understand mechanisms of cancer pathogenesis, and to improve cancer diagnosis and treatment.
28. März 2024 · Matt Meyerson is a professor of genetics and pathology, and the director of the Center for Cancer Genome Discovery at Dana-Farber Cancer Institute. He has published numerous papers on cancer genomics, epigenetics, and drug discovery.
Matthew Langer Meyerson is a professor of genetics and medicine at Harvard Medical School. He studies genomic and infectious causes of human cancers, especially lung cancer, and develops new therapies based on cancer genome analysis.
